J
Janux Therapeutics, Inc. (JANX)
NGM – Real Time Price. Currency in USD
14.41
+0.18 (1.26%)
At close: May 12, 2026, 4:00 PM EDT
14.41
0.00 (0.00%)
After-hours: May 12, 2026, 4:20 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
14.41
+0.18 (1.26%)
At close: May 12, 2026, 4:00 PM EDT
14.41
0.00 (0.00%)
After-hours: May 12, 2026, 4:20 PM EDT
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company’s clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor that is in Phase 1 clinical trial for the treatment of various solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. It also develops JANX011, a CD19-targeted adaptive immune response modulator that is in phase 1 clinical study developed for autoimmune diseases. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates; and Bristol Myers Squibb to develop and commercialize an undisclosed, novel tumor-activated therapeutic targeting a validated solid tumor antigen expressed across several human cancer types. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
| Name | Position |
|---|---|
| Dr. David Alan Campbell Ph.D. | President, Co-Founder, CEO & Director |
| Dr. Thomas Diraimondo Ph.D. | Chief Scientific Officer |
| Dr. William Y. Go M.D., Ph.D. | Chief Medical Officer |
| Mr. Charles M. Winter | Chief Technical Officer |
| Mr. James Pennington | General Counsel & Corporate Secretary |
| Mr. Matt Whitmire | Vice President of Finance |
| Ms. Janeen Doyle | Chief Corporate & Business Development Officer |
| Ms. Maria Dobek | Vice President of Accounting |
| Date | Type | Document |
|---|---|---|
| 2026-05-07 | 8-K | janx-20260507.htm |
| 2026-04-28 | DEFA14A | janx_defa14a_2026_non_xb.htm |
| 2026-04-28 | ARS | 2025_10-k_ars.pdf |
| 2026-02-26 | S-8 | janx-20260226.htm |
| 2026-02-26 | 8-K | janx-20260226.htm |
| 2026-01-22 | 8-K | janx-20260121.htm |
| 2025-11-06 | 10-Q | janx-20250930.htm |
| 2025-09-19 | 8-K | janx-20250918.htm |
| 2025-08-07 | 8-K | janx-20250807.htm |
| 2025-08-07 | 10-Q | janx-20250630.htm |